Luke Evnin Sells 76,928 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Posted by Stacy Sanders on Jun 12th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 76,928 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $0.37, for a total value of $28,463.36. Following the sale, the director owned 300,283 shares in the company, valued at approximately $111,104.71. The trade was a 20.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $24,218.80.
On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $9,978.40.
On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total value of $8,831.68.
On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $12,494.58.
On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $37,815.73.
On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,650.20.
On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.
On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total value of $38,808.96.
On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $31,936.50.

Werewolf Therapeutics Stock Up 8.0%

Shares of HOWL opened at $0.39 on Friday. Werewolf Therapeutics, Inc. has a 52 week low of $0.36 and a 52 week high of $2.38. The company has a market capitalization of $19.16 million, a price-to-earnings ratio of -0.32 and a beta of 0.29. The stock’s 50-day moving average price is $0.67 and its 200-day moving average price is $0.72.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. As a group, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.75.

Check Out Our Latest Analysis on Werewolf Therapeutics

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently bought and sold shares of HOWL. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter worth about $79,000. Marshall Wace LLP acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $113,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $48,000. Jane Street Group LLC acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $409,000. Finally, Bank of America Corp DE raised its holdings in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.